Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

Neurol Neuroimmunol Neuroinflamm 2018;5:e445. doi:10.1212/NXI.0000000000000445

In the Article "Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod" by M. Nakhaei-Nejad et al.¹, there are typographical errors in the Abstract, which should use "CD4⁺", "CD8⁺", "CD27⁺IgD⁺", and "CD27⁺" rather than "CD41," "CD81," "CD271IgD2," and "CD271" as originally published. The publisher regrets the errors.

Reference

1. Nakhaei-Nejad M, Barilla D, Lee CH, Blevins G, Giuliani F. Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e432.

Neurology[®] Neuroimmunology & Neuroinflammation

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

Neurol Neuroimmunol Neuroinflamm 2018;5;
DOI 10.1212/NXI.0000000000000445

This information is current as of January 31, 2018

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/5/2/e445.full.html
References	This article cites 1 articles, 0 of which you can access for free at: http://nn.neurology.org/content/5/2/e445.full.html##ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2018 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.